Alemtuzumab in T-cell large granular lymphocyte leukaemia
Mené sur 25 patients atteints d'une leucémie à grands lymphocytes granuleux T, cet essai de phase II évalue l'efficacité, du point de vue de la réponse hématologique à 3 mois, et la toxicité de l'alemtuzumab, un anticorps monoclonal anti CD52
T-cell large granular lymphocyte leukaemia (T-LGL) is an indolent lymphoproliferative disorder characterised by the abnormal, clonal proliferation of large granular lymphocytes. The lymphocytes are usually positive for CD3, CD8, and CD57, suggesting a cytotoxic T-cell immunophenotype, and clonality can be established with a T-cell receptor (TCR) rearrangement study. Patients with T-LGL typically present with mild cytopenias, most commonly neutropenia (52–84%) or anaemia (25–89%). Patients frequently present with concomitant autoimmune disorders, most commonly rheumatoid arthritis (11–36%).
The Lancet Haematology , commentaire, 2014